news aktuell GmbH

Semdor Pharma Group: Semdor Pharma adds Global Pharmaceutical Executive Rolf Hoffmann to its Board of Directors

29.3.2021 14:22:54 CEST | news aktuell GmbH | Press release

Share
30-year pharma veteran Rolf Hoffmann, formerly senior global executive at Amgen and Eli Lilly, joins Semdor Pharma as investor and commercial expert.

(Cologne, Germany): Semdor Pharma Group announced today that it has added Rolf Hoffmann, a seasoned global pharma executive and advisor, to its Board of Directors, as well as an investor in the company. Mr. Hoffmann previously served at Amgen as Senior Vice President of Commercial Operations (US) and SVP of International and Europe, where he focused on operations, scaling and organizational development. Mr. Hoffmann started his pharmaceutical career at Eli Lilly as a sales representative, progressing quickly to senior positions including President of Latin America Operations and General Manager in Germany. Since parting from Amgen in 2016, Mr. Hoffmann has served on numerous boards related to the pharmaceutical and biotechnical sector, including STADA (Germany's largest independent Generics/OTC enterprise), Danish Genmab (Europe's largest Biotech company) and EUSA Pharma (a European specialty pharmaceutical company focused on oncology and oncology supportive care), among others.

“Semdor Pharma attracted me because of their clear mission of building a next-generation European specialty pharmaceutical company focused on the massive problem of physical and mental pain and suffering. No other condition takes such a large emotional and financial toll on European society and Semdor’s reason for being is clear. No other European platform is able to offer the market such a broad array of life-enhancing medicines, from traditional pain medications to the exploding area of medical cannabis products. Semdor has a generational opportunity and I am excited to impart my experience scaling pharma businesses as a Board Director and investor”, said Rolf Hoffmann.

“I am proud of the hard work of every member of the Semdor team and our mission remains clear: offering European patients the most innovative, highest quality pain medicine and related products, whether traditional pain therapies or medical cannabis. We are in a stronger position than ever to build Semdor’s platform, including the Cannamedical brand, as a leader in the European medical cannabis industry” said David Henn, CEO of Semdor “With over 30 year of experience helping develop pharma platforms in Europe, North America and Latin America, , Rolf is a perfect fit as an investor and Board Director.”

About Semdor Pharma Group

The formation of Semdor Pharma Group in January 2021 established one of Europe's leading pharmaceutical groups specialized in narcotics and medical cannabis. Semdor Pharma Group was formed through the merger of the German narcotics services market leader PS Group (including subsidiaries PS Pharma Services, PB Pharma and PS Marketing & Outsourcing) and Cannamedical Pharma, which is the leading independent medical cannabis brand in Germany. Semdor offers European wholesalers, suppliers and pharmacies the broadest array of narcotic medicines (both synthetic and natural) and provides key narcotic and medical cannabis players the broadest selection of market-leading product importing, handling, packaging and formulation services. Semdor Phamra generates gross annual sales of more than 60 million euros and employs 180 team members in Cologne and Meerbusch, Germany.

Contacts

Leonie Weskott
E-Mail: presse@semdor-group.com
Phone: +49 (0) 221 9999 6151

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Infomaniak and Gruyère Energie develop a data center project in Bulle designed to limit its footprint13.11.2026 13:41:04 CET | Press release

Geneva and Bulle, 13 November 2026 – Infomaniak SA (SIX: INFO), a Swiss cloud provider, and Gruyère Energie SA announce that the planning application for a data center in Bulle will be put on public display on 13 November. Planned for 2028, this next-generation facility is intended to meet growing digital needs while reusing the heat produced by its servers in the existing district heating network. Its planned IT capacity of 2.5 megawatts (MW) is twice that of Infomaniak’s most recent data center, in Geneva. The project remains modest in size.

HEIDELBERG sees sequential improvement in business performance in a challenging geopolitical environment12.11.2026 09:07:04 CET | Press release

• Incoming orders high in second quarter of financial year 2026/2027 and around 3 percent higher after six months compared with equivalent period of previous year • Sequential increase in sales and EBITDA margin during financial year • Focus on strategic priorities – integration of manroland sheetfed proceeding according to plan • Geopolitical crises and advance outlay hit profitability • Forecast for financial year 2026/2027 – stable sales and adjusted EBITDA margin of between 5.6 and 6.6 percent

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye